A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunology of Psoriasis

(2014) Michelle A. Lowes et al.   Annual Review of Immunology

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

(2013) B. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment

(2012) Sonia A. Lamel et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

(2012) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY